Abbvie is coming up with some encouraging news from their phase III study evaluating the efficacy and safety of Venetoclax in combination with Mabthera/Rituxan compared to Bendamustine
Venetoclax or in brand name terms: Venclexta in the USA and Venclyxto in Europe, is an oral treatment consisting of a small molecule that, highly selectively, inhibits the BCL-2 protein.
The treatment is designed for patients who suffer from chronic lymphocytic leukaemia (the most common form of Leukaemia) having a specific chromosomal abnormality also known as the 17p depletion and who are not responding to the current treatment.
BCL-2 is part of a family of regulatory proteins involved in the regulation of programmed cell death (Apoptosis), either by inducing pro-apoptotic mechanism or inhibiting anti-apoptotic processes in the cell. BCL-2, in particular, is considered an important anti-apoptotic protein.
Some encouraging news for patients with CLL, will it do what Imatinib did for CML ?- time will tell!